Proton pump inhibitors - Their pharmacological impact on the clinical management of acid-related disorders

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 6, 2009, Pages 271-282

  Klotz, Ulrich ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Esomeprazole; Helicobacter pylori infection; Lansoprazole; Omeprazole; Pantoprazole; Peptic ulcer; Proton pump inhibitors, pharmacodynamics, pharmacokinetics; Rabeprazole; Reflux disease

Indexed keywords

ACETYLSALICYLIC ACID; CARBAMAZEPINE; CLARITHROMYCIN; CLOPIDOGREL; CYANOCOBALAMIN; CYCLOOXYGENASE 2 INHIBITOR; DAPSONE; DIAZEPAM; DIGOXIN; ESOMEPRAZOLE; FLUCONAZOLE; FLUVOXAMINE; KETOCONAZOLE; LANSOPRAZOLE; MEFLOQUINE; METHOTREXATE; MOCLOBEMIDE; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROGUANIL; PROTON PUMP INHIBITOR; PYRIMETHAMINE; RABEPRAZOLE; SULFADOXINE; TINIDAZOLE; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; CARCINOID; CELL HYPERPLASIA; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG POTENCY; ENZYME INDUCTION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; INTERSTITIAL NEPHRITIS; NAUSEA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRACTICE GUIDELINE; RASH; REVIEW; STOMACH ACID SECRETION; STOMACH PH; TOXIC HEPATITIS; ZOLLINGER ELLISON SYNDROME;

EID: 68549123433     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296397     Document Type: Review

References (164)

1. Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. AmJ Gastroenterol. 2005;100:207-219 (Pubitemid 41623290)
2. Arayne MS, Sultana N, Qureshi MS, Naseem S. Interaction studies of omeprazole with mefloquine, pyrimethamine and sulfadoxine. Pak J PharmSci. 2006;19:314-321
3. Ariizumi K, Ohara S, Koike T, Inomata Y, Iijima K, Sekine H, et al. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol. 2006;21:1428-1434 (Pubitemid 44154712)
4. Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord. 2005; 5 Suppl 2;S18-S30.
5. Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, van Tonningen MR, Clementi M, et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther. 2005;21:269-275 (Pubitemid 40278364)
6. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther. 2005;21:677-686 (Pubitemid 40468995)
7. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut. 1992;33:118-124
8. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769-784 (Pubitemid 44352242)
9. Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O., et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005;21:805-812 (Pubitemid 40477240)
10. BrownTJ,Hooper L, Elliott RA, Payne K,Webb R, Roberts C, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess. 2006;10:iii-xiii,1-183. (Pubitemid 44801211)
11. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345-351 (Pubitemid 20219089)
12. Bytzer P, BlumA, De Herdt D, Dubois D; The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181-188
13. Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers. Pharmacol Res. 2004;49:493-499 (Pubitemid 38283871)
14. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP, et al. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005;100:1696-1701. (Pubitemid 41648420)
15. Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22:193-202. (Pubitemid 41153061)
16. Castro Fernández M, García Díaz E, Larraona JL, Rodríguez Hornillo MC, Lamas Rojas E, Núñez Hospital D, et al. Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. Rev Esp. Enferm Dig. 2006;98:170-179
17. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. AmJ Gastroenterol. 2007;102:1808-1825 (Pubitemid 47206706)
18. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-958 (Pubitemid 35168437)
19. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852-859
20. Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2006;18: CD005415. (Pubitemid 46841303)
21. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther. 2003;17:1521-1528 (Pubitemid 36831443)
22. Esplugues JV, Marti-Cabrera M, Ponce J. Safety of proton pump inhibitors. Med Clin (Barc.). 2006;127:790-795
23. Ferguson DD, DeVault KR. Medical management of gastroesophageal reflux disease. Expert Opin Pharmacother. 2007;8:39-47. (Pubitemid 46070827)
24. Fisher L, Fisher A, Pavli P, Davis M. Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther. 2007;25:297-308. (Pubitemid 46115399)
25. Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005;11:3091-3098 (Pubitemid 40790669)
26. Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008; 47:1-6.
27. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003;17 Suppl B:36B-40B.
28. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line protonpump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147:553-562 (Pubitemid 351664506)
29. FujiokaT, YoshiiwaA, OkimotoT, KodamaM,Murakami K. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J Gastroenterol. 2007; 42,Suppl 17:3-6. (Pubitemid 46140355)
30. Furuta T, Shirai N, Watanabe F,Honda S, Takeuchi K, Iida T, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72:453-460 (Pubitemid 35178870)
31. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007; 8:1199-1210 (Pubitemid 47578229)
32. García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132:498-506. (Pubitemid 46274667)
33. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, et al. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole . J Clin Gastroenterol. 2006;40:515-520 (Pubitemid 44318136)
34. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 2008;51:256-260
35. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004;16:89-99. (Pubitemid 39043708)
36. Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis . Dig Liver Dis. 2004;36:253-259 (Pubitemid 41115474)
37. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21:795-804.
38. Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007;75 Suppl 1: 69-78.
39. Goh KL, Benamouzig R, Sander P, Schwan T; EMANCIPATE. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol. 2007;19:205-211 (Pubitemid 46263276)
40. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452-1458 (Pubitemid 44895413)
41. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950-955 (Pubitemid 46762758)
42. Gurbel PA, Lau WC, Tantry US. Omeprazole - a possible new candidate influencing the antiplatelet effect of clopidogrel. J AmColl Cardiol. 2008;51:261-263
43. Harrias BN, West DS, Johnson J, Hong SH, Stowe CD. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. Manag Care Pharm. 2004;10:449-455
44. Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxico l. 2004;94:106-111
45. Höer A, Gothe H, Schiffhorst G, Sterzel A, Grass U, Häussler B. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf. 2007;16:854-858 (Pubitemid 47322584)
46. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard- dose rabeprazole and high-dose omeprazole in gastro- oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:479-485 (Pubitemid 34214527)
47. Holtmann G, Howden CW. Review article: management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication . Aliment Pharmacol Ther. 2004;19 Suppl 1:66-70.
48. Horn J. Review article: relationship between the metabolismand efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther. 2004;20(Suppl. 6): 11-19 (Pubitemid 39593283)
49. HornJR, HowdenCW. Reviewarticle: similarities and differences among delayed-release proton-pump inhibitor formulations . Aliment Pharmacol Ther. 2005;22 Suppl. 3: 20-24
50. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther. 1990;4:25-33. (Pubitemid 20232687)
51. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247 (Pubitemid 44497506)
52. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary nonhaem iron in hereditary haemochromatosis. Gut. 2007;56:1291-1295 (Pubitemid 47300432)
53. Ishino Y, Sugano K. [Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton-pump inhibitors or H2 receptor antagonists]. Nippon Rinsho. 2007;65:891-894
54. Iwakiri K, Kawami N, Tanaka Y, Sano H, Kotoyori M, Sakamoto C. Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor. Nippon Rinsho. 2007;65:913-920
55. Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S, et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005;50:357-365 (Pubitemid 40311548)
56. Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006;98:4-19.
57. Ji S, Kim HS, Kim JW, Jee MK, Park KW, Uh Y, et al. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J Gastroenterol Hepatol. 2006;21:1381-1387 (Pubitemid 44154704)
58. Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005;50:1185-1193 (Pubitemid 41184741)
59. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002;58:453-458 (Pubitemid 35244918)
60. Kang BC, Yang CQ, Cho HK, Suh OK, ShinWG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. BiopharmDrug Dispos. 2002;23:77-81.
61. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007;25: 617-628 (Pubitemid 46255854)
62. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003;17:965-973 (Pubitemid 36459609)
63. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki H, Kayaba S, et al. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol. 2007;22:222-6. [63a] Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951-959 (Pubitemid 46181352)
64. Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol. 2005;20:11-25. (Pubitemid 40143628)
65. Kim JI, Cheung DY, Cho SH, Park SH, Han JY, Kim JK, et al. Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial. Dig Dis Sci. 2007;52: 3371-3376 (Pubitemid 350077200)
66. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, et al. Relative potency of proton pump inhibitors - comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31.
67. Kirsch C, Morgner A, Miehlke S. Relevance of cytochrome P450 polymorphisms in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease. Curr Pharmacogenom. 2006;4:47-56.
68. Klotz U. The changing target in the treatment of peptic ulcer: from pH to Hp. In: Gupta, editor. Pharmacology and therapeutics in the New Millenium. New Delhi, India: 2001; p. 587-598
69. Klotz U. The interaction potential of proton pump inhibitors. Verdauungskrankheiten. 2002;20:26-31. (Pubitemid 34160656)
70. Klotz U. Proton pump inhibitors - a pharmacological and clinical comparison. Verdauungskrankheiten. 2004;22: 112-120 (Pubitemid 38639255)
71. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori . Clin Pharmacokinet. 2000;38:243-270 (Pubitemid 30156624)
72. Klotz U. Impact of CYP2C19 polymorphisms for the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol. 2009;65:1-2.
73. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95:2-8. (Pubitemid 38993131)
74. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a reviewof a special problem. Int J Clin Pharmacol Ther. 2006;44:297-302. (Pubitemid 44043771)
75. Kuipers EJ, Proton pump inhibitors and gastric neoplasia. Gut. 2006;55:1217-1221 (Pubitemid 44277346)
76. Kumar R, Tandon VR, Bano G, Kapoor B, Sharma S, Gupta Y. Comparative study of proton pump inhibitors for triple therapy in H. pylori eradication. Indian J Gastroenterol. 2007;26:100-101 (Pubitemid 46910518)
77. Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase- 2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731-1738 (Pubitemid 44893570)
78. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment . Curr Med Res Opin. 2007;23:163-173 (Pubitemid 46201599)
79. Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007;54:18-30. (Pubitemid 47177035)
80. Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2004;3:CD002094.
81. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of protonpump inhibitor therapy for peptic ulcer bleeding in Asia-a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther. 2005;21:1055-1061 (Pubitemid 40646530)
82. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ. 2005;330:568 (Epub Jan 31). (Pubitemid 40380350)
83. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006:25:CD002094.
84. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286-296 (Pubitemid 46348929)
85. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827 (Pubitemid 38955611)
86. Li ZS, Zhan XB, Xu GM, Cheng NN, Liao Z. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol. 2007;22:815-820 (Pubitemid 46911022)
87. Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs-focus on rabeprazole. J Gastroenterol Hepatol. 2005;20 Suppl:S22-8.
88. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin-stimulated acid secretion in man. Gut. 1983;24:270-276 (Pubitemid 13159786)
89. Louw JA. Peptic ulcer disease. Curr Opin Gastroenterol. 2006;22:607-611
90. Lüth S, Teyssen S, Kölbel CB, Singer MV. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease - A pilot study. Z Gastroenterol. 2001; 39:279-281 (Pubitemid 32405411)
91. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El- Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772-781 (Pubitemid 46854190)
92. Martin de Argila C. Safety of potent gastric acid inhibition. Drugs . 2005;65 Suppl 1:97-104.
93. McCarthy DM. Management of bleeding peptic ulcer: current status of intravenous proton pump inhibitors. Best. Pract Res Clin Gastroenterol. 2004;18 Suppl:7-12.
94. Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep. 2005;7: 115-120 (Pubitemid 40500631)
95. Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. AmJ Gastroenterol. 2007;102:642-653 (Pubitemid 46328170)
96. Miura M, Satoh S, Tada H, Habuchi T, Suzuki T. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol. 2006;62:113-117
97. Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan . Aliment Pharmacol Ther. 2007;26:69-77. (Pubitemid 46889840)
98. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006,367:2086-2100
99. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet. 2007;370:1010-1012 (Pubitemid 47419006)
100. Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther. 2006;24:1439-1444 (Pubitemid 44657120)
101. Murthy S, Keyvani L, Leeson S, Targownik LE. Intravenous versus high-dose oral proton pump inhibitor therapy after endoscopic hemostasis of high-risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding. Dig Dis Sci . 2007;52:1685-1690 (Pubitemid 46870570)
102. Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 2006;29:119-132 (Pubitemid 43213886)
103. Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 2007;25:501-510 (Pubitemid 46184464)
104. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:261-273 (Pubitemid 34146367)
105. Ohkusa T, Maekawa T, Arakawa T, Nakajima M, Fujimoto K, Hoshino E, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther. 2005;21:1331-1339 (Pubitemid 40813679)
106. Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, et al. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance openlabel, low-dose therapy with rabeprazole. Dig Liver Dis. 2005;37:741-750
107. Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment Pharmacol Ther. 2007;26:195-204.
108. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. AmJ Gastroenterol. 2006;101:1467-1475 (Pubitemid 43980617)
109. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL, Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507-1514 (Pubitemid 36831441)
110. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006;4:130-142 (Pubitemid 43199681)
111. Pettit M. Treatment of gastroesophageal reflux disease. PharmWorld Sci. 2005;27 432-435
112. Peura DA, Gudmundson J, Siepmann N, Pilmer BL, Freston J. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci. 2007;52:983-987 (Pubitemid 46481236)
113. Pilliano PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust. 2000;172:16-18 (Pubitemid 30043106)
114. Pilotto A, Franceschi M, Leandro G, Scarcelli C, D'Ambrosio LP, Paris F, et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007;13:4467-4472 (Pubitemid 47412409)
115. Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, et al. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol. 2006;62:107-112
116. Ramdani A, Mignon M, Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol. 2002;26:355-359 (Pubitemid 34555809)
117. Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755-760 (Pubitemid 47385871)
118. Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther. 2004;20 Suppl 6:30-37
119. Sachs G, Shin JM, Howden CW. Reviewarticle: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23 Suppl 2:2-8.
120. Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005;59:302-309 (Pubitemid 40388085)
121. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. PharmRes. 2001;18:721-727 (Pubitemid 32783506)
122. Sánchez Garrido A. Omeprazole-induced acute cholestatic hepatitis. Gastroenterol Hepatol. 2007;30:54.
123. Savarino V, Savarino E, Parodi A, Dulbecco P. Functional heartburn and non-erosive reflux disease. Dig Dis. 2007; 25:172-174 (Pubitemid 350194162)
124. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369:1580-1581
125. Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006;51:844-850 (Pubitemid 44030800)
126. Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avron J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006;79:379-388
127. Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Invest. 2007;27:287-296 (Pubitemid 46440301)
128. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004;76:201-209 (Pubitemid 39221794)
129. Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther. 2005;78: 627-634 (Pubitemid 41773638)
130. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol. 2008;64:233-252
131. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics . Eur J Clin Pharmacol. 2008;64:935-951
132. Shimatani T, Inoue M, Kuroiwa T, Xu J, Tazuma S, Horikawa Y, et al. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. Dig Dis Sci. 2005;50:1202-1206 (Pubitemid 41184743)
133. Shimatani T, Moriwaki M, Xu J, Tazuma S, Inoue M. Acidsuppressive effects of rabeprazole: comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis. 2006;38:802-808 (Pubitemid 44430926)
134. Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006;62:597-603. (Pubitemid 44127987)
135. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545-553 (Pubitemid 47174291)
136. Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, DurhamS, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48:322-328 (Pubitemid 36232999)
137. Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. AmJ Med. 2006;119:448.e27-e36.
138. Spiegel BM, Dulai GS, Lim BS, Mann N, Kanwal F, Gralnek IM. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol. 2006;4:988-997 (Pubitemid 44137436)
139. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2004; 78:290-301. (Pubitemid 39313119)
140. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008;53:385-393 (Pubitemid 351170020)
141. Treiber G, Malfertheiner P, Klotz U. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother. 2007;8:329-350. (Pubitemid 46259892)
142. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J AmColl Cardiol. 2008;51:1925-1934 (Pubitemid 351636443)
143. Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br. J Clin Pharmacol. 2006;61:309-314 (Pubitemid 43382630)
144. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146:556-563 (Pubitemid 351650536)
145. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20:99-107. (Pubitemid 38938723)
146. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900-1920 (Pubitemid 44166604)
147. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;3:CD002095.
148. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83. (Pubitemid 44306164)
149. WaldumHL, Qvigstad G. Proton pump inhibitors and gastric neoplasia. Gut. 2007;56:1019-1020 (Pubitemid 46999090)
150. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, et al. St John's wort induces both cytochrome P450 3A4- catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75:191-197 (Pubitemid 38314868)
151. Wang X, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion. 2006;73: 178-186 (Pubitemid 44155921)
152. Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol. 2006;62:685-691 (Pubitemid 44289497)
153. Wong VW, Chan FK. 10 day sequential therapy was more effective than 10 day triple drug therapy for eradicating Helicobacter pylori infection. Evid Based Med. 2007;12: 146. (Pubitemid 47611219)
154. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9:539-549
155. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953 (Pubitemid 46021498)
156. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133: 748-754 (Pubitemid 47374135)
157. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004;44:1223-1229 (Pubitemid 39391480)
158. Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, et al. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004;57:487-494 (Pubitemid 38519654)
159. Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract. Gastroenterol Hepatol. 2006;3:80-89
160. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007;56:475-479 (Pubitemid 46580501)
161. Zapata-Colindres JC, Zepeda-Gómez S, Montaño-Loza A, Vázquez-Ballesteros E, de Jesús Villalobos J, Valdovinos- Andraca F. The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can. J Gastroenterol. 2006;20:277-280
162. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532-541
163. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-1357 (Pubitemid 47517826)
164. Zullo A, Hassan C, Campo SM, Morini S. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging. 2007;24:815-828 (Pubitemid 47553791)